Widening the Prostacyclin Paradigm : Tissue Fibroblasts Are a Critical Site of Production and Antithrombotic Protection
BACKGROUND: Prostacyclin is a fundamental signaling pathway traditionally associated with the cardiovascular system and protection against thrombosis but which also has regulatory functions in fibrosis, proliferation, and immunity. Prevailing dogma states that prostacyclin is principally derived from vascular endothelium, although it is known that other cells can also synthesize it. However, the role of nonendothelial sources in prostacyclin production has not been systematically evaluated resulting in an underappreciation of their importance relative to better characterized endothelial sources.
METHODS: To address this, we have used novel endothelial cell-specific and fibroblast-specific COX (cyclo-oxygenase) and prostacyclin synthase knockout mice and cells freshly isolated from mouse and human lung tissue. We have assessed prostacyclin release by immunoassay and thrombosis in vivo using an FeCl3-induced carotid artery injury model.
RESULTS: We found that in arteries, endothelial cells are the main source of prostacyclin but that in the lung, and other tissues, prostacyclin production occurs largely independently of endothelial and vascular smooth muscle cells. Instead, in mouse and human lung, prostacyclin production was strongly associated with fibroblasts. By comparison, microvascular endothelial cells from the lung showed weak prostacyclin synthetic capacity compared with those isolated from large arteries. Prostacyclin derived from fibroblasts and other nonendothelial sources was seen to contribute to antithrombotic protection.
CONCLUSIONS: These observations define a new paradigm in prostacyclin biology in which fibroblast/nonendothelial-derived prostacyclin works in parallel with endothelium-derived prostanoids to control thrombotic risk and potentially a broad range of other biology. Although generation of prostacyclin by fibroblasts has been shown previously, the scale and systemic activity was unappreciated. As such, this represents a basic change in our understanding and may provide new insight into how diseases of the lung result in cardiovascular risk.
| Errataetall: |
CommentIn: Arterioscler Thromb Vasc Biol. 2024 Jan;44(1):287-289. - PMID 37970715 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Arteriosclerosis, thrombosis, and vascular biology - 44(2024), 1 vom: 12. Jan., Seite 271-286 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vinokurova, Maria [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 06.03.2024 published: Print-Electronic CommentIn: Arterioscler Thromb Vasc Biol. 2024 Jan;44(1):287-289. - PMID 37970715 Citation Status MEDLINE |
|---|
| doi: |
10.1161/ATVBAHA.123.318923 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363163131 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363163131 | ||
| 003 | DE-627 | ||
| 005 | 20240306232451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/ATVBAHA.123.318923 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM363163131 | ||
| 035 | |a (NLM)37823267 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vinokurova, Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Widening the Prostacyclin Paradigm |b Tissue Fibroblasts Are a Critical Site of Production and Antithrombotic Protection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Arterioscler Thromb Vasc Biol. 2024 Jan;44(1):287-289. - PMID 37970715 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Prostacyclin is a fundamental signaling pathway traditionally associated with the cardiovascular system and protection against thrombosis but which also has regulatory functions in fibrosis, proliferation, and immunity. Prevailing dogma states that prostacyclin is principally derived from vascular endothelium, although it is known that other cells can also synthesize it. However, the role of nonendothelial sources in prostacyclin production has not been systematically evaluated resulting in an underappreciation of their importance relative to better characterized endothelial sources | ||
| 520 | |a METHODS: To address this, we have used novel endothelial cell-specific and fibroblast-specific COX (cyclo-oxygenase) and prostacyclin synthase knockout mice and cells freshly isolated from mouse and human lung tissue. We have assessed prostacyclin release by immunoassay and thrombosis in vivo using an FeCl3-induced carotid artery injury model | ||
| 520 | |a RESULTS: We found that in arteries, endothelial cells are the main source of prostacyclin but that in the lung, and other tissues, prostacyclin production occurs largely independently of endothelial and vascular smooth muscle cells. Instead, in mouse and human lung, prostacyclin production was strongly associated with fibroblasts. By comparison, microvascular endothelial cells from the lung showed weak prostacyclin synthetic capacity compared with those isolated from large arteries. Prostacyclin derived from fibroblasts and other nonendothelial sources was seen to contribute to antithrombotic protection | ||
| 520 | |a CONCLUSIONS: These observations define a new paradigm in prostacyclin biology in which fibroblast/nonendothelial-derived prostacyclin works in parallel with endothelium-derived prostanoids to control thrombotic risk and potentially a broad range of other biology. Although generation of prostacyclin by fibroblasts has been shown previously, the scale and systemic activity was unappreciated. As such, this represents a basic change in our understanding and may provide new insight into how diseases of the lung result in cardiovascular risk | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a endothelial cells | |
| 650 | 4 | |a fibroblasts | |
| 650 | 4 | |a immunoassay | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a thrombosis | |
| 650 | 7 | |a Epoprostenol |2 NLM | |
| 650 | 7 | |a DCR9Z582X0 |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Prostaglandins I |2 NLM | |
| 700 | 1 | |a Lopes-Pires, Maria Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cypaite, Neringa |e verfasserin |4 aut | |
| 700 | 1 | |a Shala, Fisnik |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Paul C |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmetaj-Shala, Blerina |e verfasserin |4 aut | |
| 700 | 1 | |a Elghazouli, Youssef |e verfasserin |4 aut | |
| 700 | 1 | |a Nüsing, Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yingbi |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Chuan-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Herschman, Harvey R |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Jane A |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkby, Nicholas S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arteriosclerosis, thrombosis, and vascular biology |d 1995 |g 44(2024), 1 vom: 12. Jan., Seite 271-286 |w (DE-627)NLM074658522 |x 1524-4636 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:1 |g day:12 |g month:01 |g pages:271-286 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/ATVBAHA.123.318923 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 1 |b 12 |c 01 |h 271-286 | ||